Clinical Trials:

NCT05925530 MDT-Bridge: AstraZeneca. Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE). Global Surgical Principal Investigator, Site PI.

NCT04062708 Alliance Foundation Trial 46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Lung Cancer. Study Chair.

NCT03604991: ECOG-ACRIN EA2174, “A Phase II Study of Peri-operative Nivolumab and lpilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma. Principal Investigator: Jennifer Eads. 

Role: Alliance Study Champion/National Co-Chair.

NCT 02856581 Alliance Trial A211401 Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients with Newly Diagnosed Lung Cancer Who Smoke Cigarettes (closed)

NCT02468024 Stablemates Trial: Sublobar Resection vs. SBRT for high risk operable early stage lung cancer (closed)

NCT03425643 Keynote 671: Efficacy and Safety of Pembrolizumab with Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants with Resectable stage IIB or IIIA Non-Small Cell Lung Cancer (closed)

NCT02194738 ALCHEMIST Trial and related trials (ANVIL, et al.)

NCT03228537 SWOG 1619: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma (closed)

NCT04241315 ELUCIDATE: Enabling LUng Cancer IDentification Using folATE Receptor Targeting. On Target Laboratories. Steering Committee, site PI. (closed)